Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

Eyewear gift vouchers available

15th December 2017

Still looking for something for that special someone? We now have gift vouchers available. The perfect present for the stylish glasses wearer in your life or for sunglasses lovers looking for stunning...

Read more

Myopia Management article by The Scotsman

11th December 2017

Article published on The Scotsman website on Thursday 23rd November 2017 Vision on: myopia care advance revealed Worrying numbers of children are becoming short-sighted. However, there are step...

Read more

Is your vision roadworthy?

20th November 2017

As part of Road Safety Week (20-16 November), the AOP (Association of Optometrists) has undertaken further research into vision standards and driving. Sadly since this story hit the news we have heard...

Read more

Diabetes and eye health

14th November 2017

Today is World Diabetes Day and unless you have the condition you may not realise the correlation between diabetes and vision. Diabetic eye disease is a group of eye conditions that can affect people ...

Read more